Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carmen Ayuso is active.

Publication


Featured researches published by Carmen Ayuso.


Inflammatory Bowel Diseases | 2011

Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity.

Jordi Rimola; Ingrid Ordás; Sonia Rodríguez; Orlando García-Bosch; Montserrat Aceituno; Josep Llach; Carmen Ayuso; Elena Ricart; Julián Panés

Background: The use of magnetic resonance imaging (MRI) for assessment of Crohns disease (CD) is expanding. The aim of this study is to define and provide an external validation of the MRI predictors of active CD, severe CD, and a quantitative Magnetic Resonance Index of Activity (MaRIA). Methods: In all, 48 patients with clinically active (n = 29) or inactive (n = 19) CD underwent ileocolonoscopy (reference standard) and MRI. T2‐weighted and pre‐ and postcontrast‐enhanced T1‐weighted sequences were acquired. Endoscopic activity was evaluated by the Crohns Disease Endoscopic Index of Severity (CDEIS), and also classified as absent, mild (inflammation without ulcers), or severe (presence of ulceration). Results: In complete agreement with a previous derivation study, independent predictors of disease severity using CDEIS as a reference were wall thickness, relative contrast enhancement (RCE), presence of edema, and ulcers on MRI. Estimation of activity in each segment using this regression model, or another with simplified coefficients (MaRIAS = 1.5*wall thickness + 0.02*RCE + 5*edema + 10*ulceration) correlated with CDEIS (r = 0.798, P < 0.001; r = 0.80 P < 0.001, respectively). In the validation cohort both indexes had a high and equal accuracy for diagnosis of active disease: receiver operator characteristic (ROC) area 0.93, sensitivity 0.87, specificity 0.87 using a cutoff point ≥7, and for diagnosis of severe disease: ROC area 0.96, sensitivity 0.92, specificity 0.92 using a cutoff point ≥11. The total of segment values (MaRIAT) correlated with global CDEIS (r = 0.83, P < 0.001). Conclusions: The MRI variables that should be evaluated in clinical practice to diagnose active CD and severe CD are validated, as well as the quantitative index of activity for use in research studies. (Inflamm Bowel Dis 2010)


Nature Genetics | 2009

Highly conserved non-coding elements on either side of SOX9 associated with Pierre Robin sequence

Sabina Benko; Judy Fantes; Jeanne Amiel; Dirk-Jan Kleinjan; Sophie Thomas; Jacqueline Ramsay; Negar Jamshidi; Abdelkader Essafi; Simon Heaney; Christopher T. Gordon; David J. McBride; Christelle Golzio; Malcolm Fisher; Paul Perry; Véronique Abadie; Carmen Ayuso; Muriel Holder-Espinasse; Nicky Kilpatrick; Melissa Lees; Arnaud Picard; I. Karen Temple; Paul Q. Thomas; Marie-Paule Vazquez; Michel Vekemans; Hugues Roest Crollius; Nicholas D. Hastie; Arnold Munnich; Heather Etchevers; Anna Pelet; Peter G. Farlie

Pierre Robin sequence (PRS) is an important subgroup of cleft palate. We report several lines of evidence for the existence of a 17q24 locus underlying PRS, including linkage analysis results, a clustering of translocation breakpoints 1.06–1.23 Mb upstream of SOX9, and microdeletions both ∼1.5 Mb centromeric and ∼1.5 Mb telomeric of SOX9. We have also identified a heterozygous point mutation in an evolutionarily conserved region of DNA with in vitro and in vivo features of a developmental enhancer. This enhancer is centromeric to the breakpoint cluster and maps within one of the microdeletion regions. The mutation abrogates the in vitro enhancer function and alters binding of the transcription factor MSX1 as compared to the wild-type sequence. In the developing mouse mandible, the 3-Mb region bounded by the microdeletions shows a regionally specific chromatin decompaction in cells expressing Sox9. Some cases of PRS may thus result from developmental misexpression of SOX9 due to disruption of very-long-range cis-regulatory elements.


Neurology | 2012

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion

Jong-Min Lee; Eliana Marisa Ramos; Ji Hyun Lee; Tammy Gillis; Jayalakshmi S. Mysore; Michael R. Hayden; Simon C. Warby; Patrick J. Morrison; Martha Nance; Christopher A. Ross; Russell L. Margolis; Ferdinando Squitieri; S. Orobello; S. Di Donato; Estrella Gomez-Tortosa; Carmen Ayuso; Oksana Suchowersky; Ronald J. Trent; Elizabeth McCusker; Andrea Novelletto; Marina Frontali; Randi Jones; Tetsuo Ashizawa; Samuel Frank; Marie Saint-Hilaire; Steven M. Hersch; H.D. Rosas; Diane Lucente; Madeline Harrison; Andrea Zanko

Objective: Age at onset of diagnostic motor manifestations in Huntington disease (HD) is strongly correlated with an expanded CAG trinucleotide repeat. The length of the normal CAG repeat allele has been reported also to influence age at onset, in interaction with the expanded allele. Due to profound implications for disease mechanism and modification, we tested whether the normal allele, interaction between the expanded and normal alleles, or presence of a second expanded allele affects age at onset of HD motor signs. Methods: We modeled natural log-transformed age at onset as a function of CAG repeat lengths of expanded and normal alleles and their interaction by linear regression. Results: An apparently significant effect of interaction on age at motor onset among 4,068 subjects was dependent on a single outlier data point. A rigorous statistical analysis with a well-behaved dataset that conformed to the fundamental assumptions of linear regression (e.g., constant variance and normally distributed error) revealed significance only for the expanded CAG repeat, with no effect of the normal CAG repeat. Ten subjects with 2 expanded alleles showed an age at motor onset consistent with the length of the larger expanded allele. Conclusions: Normal allele CAG length, interaction between expanded and normal alleles, and presence of a second expanded allele do not influence age at onset of motor manifestations, indicating that the rate of HD pathogenesis leading to motor diagnosis is determined by a completely dominant action of the longest expanded allele and as yet unidentified genetic or environmental factors. Neurology® 2012;78:690–695


Nature Genetics | 2010

AHI1 is required for photoreceptor outer segment development and is a modifier for retinal degeneration in nephronophthisis.

Carrie M. Louie; Gianluca Caridi; Vanda S. Lopes; Francesco Brancati; Andreas Kispert; Madeline A. Lancaster; Andrew M. Schlossman; Edgar A. Otto; Michael Leitges; Hermann Josef Gröne; Irma Lopez; Harini V. Gudiseva; John F. O'Toole; Elena Vallespín; Radha Ayyagari; Carmen Ayuso; Frans P.M. Cremers; Anneke I. den Hollander; Robert K. Koenekoop; Bruno Dallapiccola; Gian Marco Ghiggeri; Friedhelm Hildebrandt; Enza Maria Valente; David S. Williams; Joseph G. Gleeson

Degeneration of photoreceptors is a common feature of ciliopathies, owing to the importance of the specialized ciliary structure of these cells. Mutations in AHI1, which encodes a cilium-localized protein, have been shown to cause a form of Joubert syndrome that is highly penetrant for retinal degeneration. We show that Ahi1-null mice fail to form retinal outer segments and have abnormal distribution of opsin throughout their photoreceptors. Apoptotic cell death of photoreceptors occurs rapidly between 2 and 4 weeks of age in these mice and is significantly (P = 0.00175 and 0.00613) delayed by a reduced dosage of opsin. This phenotype also shows dosage-sensitive genetic interactions with Nphp1, another ciliopathy-related gene. Although it is not a primary cause of retinal blindness in humans, we show that an allele of AHI1 is associated with a more than sevenfold increase in relative risk of retinal degeneration within a cohort of individuals with the hereditary kidney disease nephronophthisis. Our data support context-specific roles for AHI1 as a contributor to retinopathy and show that AHI1 may explain a proportion of the variability in retinal phenotypes observed in nephronophthisis.


Archive | 2012

COHORT study oft the HSG. CAG repeat expansion in Huntington disease determines age at onset in al fully dominant fashion

Jong-Min Lee; Eliana Marisa Ramos; Ji Hyun Lee; Tammy Gillis; Jayalakshmi S. Mysore; Hayden; Simon C. Warby; Patrick J. Morrison; Martha Nance; Christopher A. Ross; Russell L. Margolis; Ferdinando Squitieri; S. Orobello; S Di Donato; Estrella Gomez-Tortosa; Carmen Ayuso; Oksana Suchowersky; Ronald J. Trent; Elizabeth McCusker; Andrea Novelletto; Marina Frontali; Randi Jones; Tetsuo Ashizawa; Samuel Frank; Marie-Helene Saint-Hilaire; Steven M. Hersch; H.D. Rosas; Diane Lucente; Madeline Harrison; Andrea Zanko

Objective: Age at onset of diagnostic motor manifestations in Huntington disease (HD) is strongly correlated with an expanded CAG trinucleotide repeat. The length of the normal CAG repeat allele has been reported also to influence age at onset, in interaction with the expanded allele. Due to profound implications for disease mechanism and modification, we tested whether the normal allele, interaction between the expanded and normal alleles, or presence of a second expanded allele affects age at onset of HD motor signs. Methods: We modeled natural log-transformed age at onset as a function of CAG repeat lengths of expanded and normal alleles and their interaction by linear regression. Results: An apparently significant effect of interaction on age at motor onset among 4,068 subjects was dependent on a single outlier data point. A rigorous statistical analysis with a well-behaved dataset that conformed to the fundamental assumptions of linear regression (e.g., constant variance and normally distributed error) revealed significance only for the expanded CAG repeat, with no effect of the normal CAG repeat. Ten subjects with 2 expanded alleles showed an age at motor onset consistent with the length of the larger expanded allele. Conclusions: Normal allele CAG length, interaction between expanded and normal alleles, and presence of a second expanded allele do not influence age at onset of motor manifestations, indicating that the rate of HD pathogenesis leading to motor diagnosis is determined by a completely dominant action of the longest expanded allele and as yet unidentified genetic or environmental factors. Neurology® 2012;78:690–695


Annals of Neurology | 2005

OPA1 R445H mutation in optic atrophy associated with sensorineural deafness

Patrizia Amati-Bonneau; Agnès Guichet; Aurélien Olichon; Arnaud Chevrollier; Frédérique Viala; Stéphanie Miot; Carmen Ayuso; Sylvie Odent; Catherine Arrouet; Christophe Verny; Marie‐Noelle Calmels; Gilles Simard; Pascale Belenguer; Jing Wang; Jean-Luc Puel; Christian P. Hamel; Yves Malthièry; Dominique Bonneau; Guy Lenaers; Pascal Reynier

The heterozygous R445H mutation in OPA1 was found in five patients with optic atrophy and deafness. Audiometry suggested that the sensorineural deafness resulted from auditory neuropathy. Skin fibroblasts showed hyperfragmentation of the mitochondrial network, decreased mitochondrial membrane potential, and adenosine triphosphate synthesis defect. In addition, OPA1 was found to be widely expressed in the sensory and neural cochlear cells of the guinea pig. Thus, optic atrophy and deafness may be related to energy defects due to a fragmented mitochondrial network. Ann Neurol 2005


Human Mutation | 2009

Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations.

Marc Ferré; Dominique Bonneau; Dan Milea; Arnaud Chevrollier; Christophe Verny; Hélène Dollfus; Carmen Ayuso; Sabine Defoort; Catherine Vignal; Xavier Zanlonghi; Jean‐Francois Charlin; Josseline Kaplan; Sylvie Odent; Christian P. Hamel; Vincent Procaccio; Pascal Reynier; Patrizia Amati-Bonneau

We report the results of molecular screening in 980 patients carried out as part of their work‐up for suspected hereditary optic neuropathies. All the patients were investigated for Lebers hereditary optic neuropathy (LHON) and autosomal dominant optic atrophy (ADOA), by searching for the ten primary LHON‐causing mtDNA mutations and examining the entire coding sequences of the OPA1 and OPA3 genes, the two genes currently identified in ADOA. Molecular defects were identified in 440 patients (45% of screened patients). Among these, 295 patients (67%) had an OPA1 mutation, 131 patients (30%) had an mtDNA mutation, and 14 patients (3%), belonging to three unrelated families, had an OPA3 mutation. Interestingly, OPA1 mutations were found in 157 (40%) of the 392 apparently sporadic cases of optic atrophy. The eOPA1 locus‐specific database now contains a total of 204 OPA1 mutations, including 77 novel OPA1 mutations reported here. The statistical analysis of this large set of mutations has led us to propose a diagnostic strategy that should help with the molecular work‐up of optic neuropathies. Our results highlight the importance of investigating LHON‐causing mtDNA mutations as well as OPA1 and OPA3 mutations in cases of suspected hereditary optic neuropathy, even in absence of a family history of the disease.


Journal of Ophthalmology | 2011

An Update on the Genetics of Usher Syndrome

José M. Millán; Elena Aller; Teresa Jaijo; Ascensión Gimenez-Pardo; Carmen Ayuso

Usher syndrome (USH) is an autosomal recessive disease characterized by hearing loss, retinitis pigmentosa (RP), and, in some cases, vestibular dysfunction. It is clinically and genetically heterogeneous and is the most common cause underlying deafness and blindness of genetic origin. Clinically, USH is divided into three types. Usher type I (USH1) is the most severe form and is characterized by severe to profound congenital deafness, vestibular areflexia, and prepubertal onset of progressive RP. Type II (USH2) displays moderate to severe hearing loss, absence of vestibular dysfunction, and later onset of retinal degeneration. Type III (USH3) shows progressive postlingual hearing loss, variable onset of RP, and variable vestibular response. To date, five USH1 genes have been identified: MYO7A (USH1B), CDH23 (USH1D), PCDH15 (USH1F), USH1C(USH1C), and USH1G(USH1G). Three genes are involved in USH2, namely, USH2A (USH2A), GPR98 (USH2C), and DFNB31 (USH2D). USH3 is rare except in certain populations, and the gene responsible for this type is USH3A.


The American Journal of Gastroenterology | 2015

Characterization of inflammation and fibrosis in Crohn's disease lesions by magnetic resonance imaging.

Jordi Rimola; Núria Planell; Sonia Rodríguez; Salvadora Delgado; Ingrid Ordás; Anna Ramírez-Morros; Carmen Ayuso; Montse Aceituno; Elena Ricart; Aranzazu Jauregui-Amezaga; Julián Panés; Miriam Cuatrecasas

Objectives:Measurement of the component of fibrosis in Crohn’s disease (CD) may have important therapeutic implications. The aim of this study was to characterize the Magnetic Resonance Imaging (MRI) findings that are differentially associated with the presence of fibrosis and those associated with inflammatory activity, using the pathological analysis of surgically resected intestinal lesions as reference standard.Methods:MRI studies with identical imaging protocol of 41 CD patients who underwent elective bowel resection within 4 months before surgery were reviewed. MRI evaluated wall thickening, edema, ulcers, signal intensity at submucosa at 70 s and 7 min after gadolinium injection, stenosis, and pattern of enhancement in each phase of the dynamic study and changes on this pattern over time. Pathological inflammatory and fibrosis scores were classified into three grades of severity.Results:In all, 44 segments from 41 patients were analyzed. The pathological intensity of inflammation was associated with the following MRI parameters: hypersignal on T2 (P=0.02), mucosal enhancement (P=0.03), ulcerations (P=0.01), and blurred margins (P=0.05). The degree of fibrosis correlated with the percentage of enhancement gain (P<0.01), the pattern of enhancement at 7 min (P<0.01), and the presence of stenosis (P=0.05). Using percentage of enhancement gain, MRI is able to discriminate between mild–moderate and severe fibrosis deposition with a sensitivity of 0.94 and a specificity of 0.89.Conclusions:MRI is accurate for detecting the presence of severe fibrosis in CD lesions on the basis of the enhancement pattern.


European Journal of Human Genetics | 2013

Informed consent for whole-genome sequencing studies in the clinical setting. Proposed recommendations on essential content and process

Carmen Ayuso; José M. Millán; Marta Mancheño; Rafael Dal-Ré

The development of new massive sequencing techniques has now made it possible to significantly reduce the time and costs of whole-genome sequencing (WGS). Although WGS will soon become a routine testing tool, new ethical issues have surfaced. In light of these concerns, a systematic review of papers published by expert authors on IC or specific ethical issues related to IC for WGS analysis in the clinical setting has been conducted using the Pubmed, Embase and Cochrane Library databases. Additionally, a search was conducted for international ethical guidelines for genetic studies published by scientific societies and ethical boards. Based on these documents, a minimum set of information to be provided to patients in the IC form was determined. Fourteen and seven documents from the database search and from scientific societies, respectively, were selected. A very high level of consistency between them was found regarding the recommended IC form content. Pre-test counselling and general information common to all genetic tests should be included in the IC form for WGS for diagnostic purposes, but additional information addressing specific issues on WGS are proposed, such as a plan for the ethical, clinically oriented return of incidental findings. Moreover, storage of additional information for future use should also be agreed upon with the patient in advance. Recommendations for WGS studies in the clinical setting concerning both the elements of information and the process of obtaining the IC as well as how to handle the results obtained are proposed.

Collaboration


Dive into the Carmen Ayuso's collaboration.

Top Co-Authors

Avatar

Rosa Riveiro-Alvarez

Instituto de Salud Carlos III

View shared research outputs
Top Co-Authors

Avatar

Marta Corton

University of Santiago de Compostela

View shared research outputs
Top Co-Authors

Avatar

Blanca Garcia-Sandoval

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Carmen Ramos

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Diego Cantalapiedra

Instituto de Salud Carlos III

View shared research outputs
Top Co-Authors

Avatar

Elena Vallespín

Hospital Universitario La Paz

View shared research outputs
Top Co-Authors

Avatar

Montserrat Baiget

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Maria Garcia-Hoyos

Instituto de Salud Carlos III

View shared research outputs
Researchain Logo
Decentralizing Knowledge